<abstract xmlns="http://www.w3.org/1999/xhtml"><p> Octapharma's core business is the development and production of human proteins from human plasma and cell lines. As the company moves into the recombinant arena, Chairman Wolfgang Marguerre discusses opportunities and threats with Editor-in-Chief Kate Khair</p></abstract>

Octapharma's core business is the development and production of human proteins from human plasma and cell lines. As the company moves into the recombinant arena, Chairman Wolfgang Marguerre discusses opportunities and threats with Editor-in-Chief Kate Khair

Octapharma’s balanced portfolio built on a very special juice

The Journal of Haemophilia Practice

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

{"article-title":"Octapharma\u2019s balanced portfolio built on a very special juice"}

Octapharma's core business is the development and production of human proteins from human plasma and cell lines. As the company moves into the recombinant...

Octapharma’s balanced portfolio built on a very special juice

Article Category: In My View

Online veröffentlicht: 21. Apr. 2018

Seitenbereich: 35 - 37

DOI: https://doi.org/10.17225/jhp.00023

© 2018

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.